{"product_id":"biogen-swot-analysis","title":"Biogen SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete SWOT Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eBiogen’s core strengths—robust neurology portfolio and strong R\u0026amp;D expertise—contrast with patent cliffs and pricing pressure, while growth hinges on pipeline execution and strategic partnerships; regulatory setbacks and competition pose key threats. Discover the full SWOT analysis for in-depth, research-backed insights, editable deliverables, and actionable recommendations to support investment, strategy, or M\u0026amp;A decisions—available for purchase now.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeadership in Neuroscience\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy end-2025 Biogen remains a neuroscience leader with ~45 years of R\u0026amp;D focus and \u0026gt;$7.5B cumulative MS franchise revenue since 2018; deep pathology expertise in multiple sclerosis and neurodegeneration drives a higher hit-rate in CNS programs versus industry averages, cutting late-stage failure risk and supporting a 2025 R\u0026amp;D pipeline of 12 CNS assets, giving a clear edge over generalist pharma in brain-science drug discovery.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlzheimer's Market Footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiogen’s Leqembi (lecanemab), co-commercialized with Eisai, secured first-mover scale in amyloid-beta therapy, driving estimated 2025 revenue run-rate of ~$1.8B across both partners and capturing early payer coverage in the US and EU.\u003c\/p\u003e\n\u003cp\u003eThe franchise is central to Biogen’s pivot from legacy neurology drugs, projected to contribute ~35% of company revenue by FY2026 as infusion and PET\/CSF diagnostic capacity expanded to cover \u0026gt;60% of target clinics worldwide by late 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Rare Disease Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe 2023 acquisition of Reata brought Skyclarys (omaveloxolone) to Biogen, opening Friedreich’s ataxia sales—estimated at $120–180M in 2025—diversifying revenue beyond neurology. Rare-disease drugs carry higher pricing power and typical exclusivity of 7–12 years, boosting margins versus mass-market meds. Skyclarys complements Spinraza (nusinersen), whose 2024 net sales were $1.8B, keeping Biogen strong in high-value niche indications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiosimilars Revenue Stream\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBiogen’s biosimilars unit generated about $450 million in revenue in 2024, offering steady cash flow that offsets R\u0026amp;D volatility from novel drug programs.\u003c\/p\u003e\n\u003cp\u003eThese products lower system costs and expand access to biologics, while Biogen’s manufacturing scale helped gain share in EU and US immunology and ophthalmology markets in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue ~$450M\u003c\/li\u003e\n\u003cli\u003eProvides predictable cash flow vs. R\u0026amp;D risk\u003c\/li\u003e\n\u003cli\u003eSupports cost containment and patient access\u003c\/li\u003e\n\u003cli\u003eManufacturing strength fuels EU\/US market gains\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Cost Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpthrough the fit for growth program biogen cut annual operating costs by about million and redirected roughly annually into r acquisitions to strengthen its neurology neuroimmunology pipeline.\u003e\u003cpa leaner structure lifted adjusted operating margin to in improving cash flow and enabling faster clinical decisions while boosting agility amid regulatory market shifts.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e$700M annual cost reduction (by 2024)\u003c\/li\u003e\n\u003cli\u003e$300–$400M reinvested per year into R\u0026amp;D\/acquisitions\u003c\/li\u003e\n\u003cli\u003eAdjusted operating margin ~28% (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pa\u003e\u003c\/pthrough\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiogen: CNS leader — $7.5B+ MS revenue, 12 assets, $1.8B Leqembi \u0026amp; Spinraza each\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBiogen leads CNS R\u0026amp;D with ~45 years’ focus, 12 CNS assets (2025), and \u0026gt;$7.5B MS revenue since 2018; Leqembi run-rate ~$1.8B (2025); Spinraza net sales $1.8B (2024); Skyclarys $120–180M (2025); biosimilars $450M (2024); Fit for Growth saved $700M (by 2024) and lifted adj. operating margin to ~28% (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCNS assets (2025)\u003c\/td\u003e\n\u003ctd\u003e12\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLeqembi run-rate (2025)\u003c\/td\u003e\n\u003ctd\u003e$1.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpinraza sales (2024)\u003c\/td\u003e\n\u003ctd\u003e$1.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSkyclarys (2025 est.)\u003c\/td\u003e\n\u003ctd\u003e$120–180M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilars (2024)\u003c\/td\u003e\n\u003ctd\u003e$450M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFit for Growth savings\u003c\/td\u003e\n\u003ctd\u003e$700M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdj. operating margin (2024)\u003c\/td\u003e\n\u003ctd\u003e~28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eAnalyzes Biogen’s competitive position by outlining its strengths, weaknesses, opportunities, and threats to provide a concise framework for strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise Biogen SWOT matrix for fast, visual strategy alignment, highlighting R\u0026amp;D strengths, pipeline risks, regulatory threats, and market opportunities for quick executive decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Product Erosion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe core multiple sclerosis franchise faces heavy erosion: Tecfidera (dimethyl fumarate) revenue fell from about $3.4B in 2016 peak to roughly $1.1B by 2024 after generics and oral rivals, leaving a multibillion-dollar gap; this forces Biogen to rely on new launches like Vumerity and Aduhelm's limited remit, so commercial execution of recently approved therapies must be near-perfect to avoid further top-line contraction—Q4 2024 sales showed overall product decline of mid-single digits year-over-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh R\u0026amp;D Risk Profile\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeuroscience has ~14% success to approval from Phase I versus ~33% in oncology (BIO\/BIOTECH 2021–2024 data), so Biogen’s heavy neuroscience focus raises R\u0026amp;D risk. A single late-stage failure recently wiped ~25% of market cap in comparable peers; Biogen remains exposed to similar binary outcomes. In 2024 Biogen spent $2.1B on R\u0026amp;D, concentrating financial risk in high-failure programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMajor portions of Biogen’s growth, especially in Alzheimer’s, depend on profit-sharing with Eisai; the EMERGE\/ENGAGE program and 2023 co-commercialization deals cap Biogen’s revenue share (roughly 45–50% on lecanemab-related sales by some estimates) and reduce total upside.\u003c\/p\u003e\n\u003cp\u003eShared control eases R\u0026amp;D cost but limits independent pricing and strategic moves, slowing pivots versus firms owning assets outright; Biogen reported R\u0026amp;D collaboration expenses of $1.2B in 2024, reflecting this trade-off.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentrated Revenue Base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBiogen still relies heavily on a few drugs: in 2024 lecanemab and Tecfidera-like franchises accounted for roughly 55% of revenue, leaving valuation concentrated in neurology and MS therapies.\u003c\/p\u003e\n\u003cp\u003eThat concentration makes Biogen highly sensitive to regulatory shifts or safety signals—an adverse label change could cut peak sales by tens of percent.\u003c\/p\u003e\n\u003cp\u003eInvestors view this limited diversification as higher risk during market turmoil or healthcare reform, pressuring valuation multiples.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~55% revenue from top 2-3 products (2024)\u003c\/li\u003e\n\u003cli\u003eHigh sensitivity to regulatory\/safety events\u003c\/li\u003e\n\u003cli\u003eSector concentration: neurology\/MS\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHistorical Pipeline Setbacks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePast drug setbacks—most notably the 2020 Aduhelm (aducanumab) controversy and its 2021 limited FDA approval—damaged Biogen’s reputation with regulators and investors, contributing to a ~60% stock drop from peak in 2021 and $3.6B goodwill impairment in FY2021.\u003c\/p\u003e\n\u003cp\u003eRebuilding trust needs consistent clinical wins and transparent safety\/efficacy reporting; otherwise new filings face higher FDA and EMA scrutiny and longer review timelines.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2021 stock decline ~60%\u003c\/li\u003e\n\u003cli\u003e$3.6B goodwill write-down FY2021\u003c\/li\u003e\n\u003cli\u003eIncreased review rigor → longer approval timelines\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug franchise collapse, concentration and neuroscience risk threaten long‑term outlook\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHeavy MS franchise erosion (Tecfidera revenue ~ $1.1B in 2024 vs $3.4B peak 2016), concentration risk (~55% revenue from top 2-3 products in 2024), high neuroscience R\u0026amp;D failure risk (Phase I→approval ~14%), reliance on co-commercialization (lecanemab revenue share ~45–50%), reputational hit from Aduhelm (2021 stock drop ~60%, $3.6B goodwill write-down).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (year)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTecfidera rev\u003c\/td\u003e\n\u003ctd\u003e$1.1B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop products share\u003c\/td\u003e\n\u003ctd\u003e~55% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase I→approval\u003c\/td\u003e\n\u003ctd\u003e~14% (2021–24)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLecanemab share\u003c\/td\u003e\n\u003ctd\u003e~45–50% (est.)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAduhelm impact\u003c\/td\u003e\n\u003ctd\u003e-60% stock \/ $3.6B write-down (2021)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eBiogen SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get; purchase unlocks the entire in-depth version. You’re viewing a live preview of the actual SWOT analysis file, and the complete, editable report becomes available after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752371401081,"sku":"biogen-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/biogen-swot-analysis.png?v=1772240158","url":"https:\/\/matrixbcg.com\/products\/biogen-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}